Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 81
Filter
Add more filters

Publication year range
1.
Int J Mol Sci ; 25(13)2024 Jun 29.
Article in English | MEDLINE | ID: mdl-39000302

ABSTRACT

Dupuytren's disease (DD) is a prevalent fibroproliferative disorder of the hand, shaped by genetic, epigenetic, and environmental influences. The extracellular matrix (ECM) is a complex assembly of diverse macromolecules. Alterations in the ECM's content, structure and organization can impact both normal physiological functions and pathological conditions. This study explored the content and organization of glycosaminoglycans, proteoglycans, and collagen in the ECM of patients at various stages of DD, assessing their potential as prognostic indicators. This research reveals, for the first time, relevant changes in the complexity of chondroitin/dermatan sulfate structures, specifically an increase of disaccharides containing iduronic acid residues covalently linked to either N-acetylgalactosamine 6-O-sulfated or N-acetylgalactosamine 4-O-sulfated, correlating with the disease's severity. Additionally, we noted an increase in versican expression, a high molecular weight proteoglycan, across stages I to IV, while decorin, a small leucine-rich proteoglycan, significantly diminishes as DD progresses, both confirmed by mRNA analysis and protein detection via confocal microscopy. Coherent anti-Stokes Raman scattering (CARS) microscopy further demonstrated that collagen fibril architecture in DD varies importantly with disease stages. Moreover, the urinary excretion of both hyaluronic and sulfated glycosaminoglycans markedly decreased among DD patients.Our findings indicate that specific proteoglycans with galactosaminoglycan chains and collagen arrangements could serve as biomarkers for DD progression. The reduction in glycosaminoglycan excretion suggests a systemic manifestation of the disease.


Subject(s)
Collagen , Decorin , Dupuytren Contracture , Proteoglycans , Humans , Dupuytren Contracture/metabolism , Dupuytren Contracture/pathology , Collagen/metabolism , Proteoglycans/metabolism , Decorin/metabolism , Extracellular Matrix/metabolism , Male , Disease Progression , Female , Dermatan Sulfate/metabolism , Middle Aged , Aged , Versicans/metabolism , Versicans/genetics , Glycosaminoglycans/metabolism , Chondroitin Sulfates/metabolism , Polysaccharides
2.
Psychogeriatrics ; 24(4): 968-982, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38638077

ABSTRACT

Behavioural and psychological symptoms of dementia (BPSD) are a clinical challenge for the lack of a sound taxonomy, frequent presentation with comorbid BPSD, lack of specific pharmacologic interventions, poor base of methodologically sound evidence with randomized clinical trials, contamination from the treatment of behavioural disturbances of young and adult psychiatric conditions, and small efficacy window of psychotropic drugs. We present here a treatment workflow based on a concept-driven literature review based on the notions that (i) the aetiology of BPSD can be mainly neurobiological (so-called 'primary' symptoms) or mainly environmental and functional ('secondary' symptoms) and that this drives treatment; (ii) the clinical efficacy of psychotropic drugs is driven by their specific profile of receptor affinity; (iii) drug treatment should follow the rules of 'start low-go slow, prescribe and revise'. This article argues in support of the distinction between primary and secondary BPSD, as well as their characteristics, which until now have been just sketchily described in the literature. It also offers comprehensive and pragmatic clinician-oriented recommendations for the treatment of BPSD.


Subject(s)
Dementia , Psychotropic Drugs , Humans , Dementia/drug therapy , Dementia/psychology , Psychotropic Drugs/therapeutic use , Aged , Behavioral Symptoms/drug therapy , Behavioral Symptoms/diagnosis , Mental Disorders/drug therapy , Mental Disorders/therapy
3.
Clin Oral Investig ; 27(11): 6321-6332, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37728616

ABSTRACT

OBJECTIVES: Endodontic treatment is one of the most fearful procedures among dentistry, and the use of music during the procedure has been evaluated to control patients' anxiety. This systematic review has been conducted to provide a synthesis of the state of knowledge in this field and aimed to answer the following question: "Can music therapy reduce patient's state anxiety during endodontic treatment?". METHODS: A search was performed in six electronic databases (PubMed, Cochrane Library, Scopus, Web of Science, EMBASE, and Open Gray) for articles published until April 2022. The eligibility criteria, based on the PICOS strategy, were as follows: (P) patients undergoing endodontic treatment; (I) exposure to music; (C) no music; (O) patients' anxiety; (S) only randomized clinical trials. The risk of bias was analyzed according to the Cochrane Risk of Bias tool for randomized controlled trials (RoB 2). The strength of evidence from the included studies was assessed using the Grading of Assessment, Development, and Assessment Recommendations (GRADE) tool. RESULTS: Five eligible studies were retrieved. A low to high risk of bias was verified. Descriptive analysis showed an effect in favor of music intervention, with differences among state anxiety, heart rate and blood pressure. CONCLUSIONS: With a very low quality of evidence, dental care professionals may consider playing background music during endodontic treatment since it is a cost-effective and easy alternative to trying to reduce dental anxiety. CLINICAL RELEVANCE: Five studies were included in this systematic review and showed, with a very low quality of evidence, that music may reduce state anxiety levels on patients during root canal treatment.


Subject(s)
Music Therapy , Music , Humans , Randomized Controlled Trials as Topic , Anxiety , Music Therapy/methods , Dental Care
4.
Rev Med Suisse ; 19(848): 2060-2065, 2023 Nov 01.
Article in French | MEDLINE | ID: mdl-37910056

ABSTRACT

Delirium is a commonly encountered syndrome in clinical practice. Older people with cognitive disorders are most at risk of developing delirium during the hospital stay. However, the risk of underdiagnosis is significant, particularly because of the overlap of behavioral symptoms and cognitive impairment between delirium and dementia. With an aging population and an ever-increasing prevalence of cognitive disorders, this article exposes the bilateral relationship maintained between dementia and delirium and bring certain diagnostic tools and clinical management clues to support the clinician. Finally, the perspectives of ongoing clinical research that could respond to current challenges are discussed.


L'état confusionnel aigu (ECA) est un syndrome fréquemment rencontré dans la pratique clinique. Les personnes âgées atteintes de troubles cognitifs sont les plus à risque de développer un ECA durant le séjour hospitalier. Le risque de sous-diagnostic est important, les symptômes comportementaux et de l'atteinte cognitive en lien avec la démence étant notamment parfois difficiles à distinguer de ceux de l'état confusionnel. Devant une population vieillissante et une prévalence de troubles cognitifs toujours grandissante, cet article aborde la relation bilatérale entretenue entre la démence et l'ECA, et propose certains outils diagnostiques et aides à la prise en charge pour le clinicien. Enfin, les perspectives de la recherche clinique en cours qui pourraient répondre aux défis actuels sont évoquées.


Subject(s)
Cognition Disorders , Cognitive Dysfunction , Delirium , Dementia , Humans , Aged , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/epidemiology , Cognitive Dysfunction/etiology , Aging , Dementia/complications , Dementia/diagnosis , Dementia/epidemiology , Delirium/diagnosis , Delirium/epidemiology , Delirium/etiology
5.
Eur J Nucl Med Mol Imaging ; 48(7): 2200-2211, 2021 07.
Article in English | MEDLINE | ID: mdl-33638661

ABSTRACT

PURPOSE: Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. METHODS: Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented before amyloid-PET. Two neurologists independently assessed all reports with a balanced randomized design, and expressed etiological diagnosis and diagnostic confidence (50-100%) three times: (i) at baseline based on the routine diagnostic workup, (ii) after the first exam (amyloid-PET for the AMY-TAU pathway, and tau-PET for the TAU-AMY pathway), and (iii) after the remaining exam. The main outcomes were changes in diagnosis (from AD to non-AD or vice versa) and in diagnostic confidence. RESULTS: Amyloid-PET and tau-PET, when presented as the first exam, resulted in a change of etiological diagnosis in 28% (p = 0.006) and 28% (p < 0.001) of cases, and diagnostic confidence increased by 18% (p < 0.001) and 19% (p < 0.001) respectively, with no differences between exams (p > 0.05). We observed a stronger impact of a negative amyloid-PET versus a negative tau-PET (p = 0.014). When added as the second exam, amyloid-PET and tau-PET resulted in a further change in etiological diagnosis in 6% (p = 0.077) and 9% (p = 0.149) of cases, and diagnostic confidence increased by 4% (p < 0.001) and 5% (p < 0.001) respectively, with no differences between exams (p > 0.05). CONCLUSION: Amyloid-PET and tau-PET significantly impacted diagnosis and diagnostic confidence in a similar way, although a negative amyloid-PET has a stronger impact on diagnosis than a negative tau-PET. Adding either of the two as second exam further improved diagnostic confidence. TRIAL NUMBER: PB 2016-01346.


Subject(s)
Alzheimer Disease , Amyloidosis , Cognitive Dysfunction , Alzheimer Disease/diagnostic imaging , Amyloid , Amyloid beta-Peptides , Humans , Positron-Emission Tomography , tau Proteins
6.
Int J Geriatr Psychiatry ; 36(6): 851-857, 2021 06.
Article in English | MEDLINE | ID: mdl-33300151

ABSTRACT

OBJECTIVES: To determine the prevalence, localization and associations of cerebral microbleeds (CMB) in dementia with Lewy bodies (DLB) with its core clinical symptoms and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). We hypothesize DLB patients with CMB have increased amyloid burden compared to those without CMB, which could also translate into clinical differences. METHODS: Retrospective cross-sectional analysis from the AlphaLewyMA study (https://clinicaltrials.gov/ct2/show/NCT01876459). Patients underwent a standardized protocol of brain MRI including 3D T1, 3D FLAIR and T2* sequences, and CSF analysis of AD biomarkers. CMB and white matter hyperintensities (WMHs) were visually assessed in prodromal and mild demented (DLB, N = 91) and AD (AD, N = 67) patients. RESULTS: CMB prevalence did not differ among DLB and AD (24.2% vs. 37.3%; p = 0.081). CMB were mainly distributed in lobar topographies in both DLB (74%) and AD (89%). CMB in DLB was not associated with global cognitive performance, executive functioning, speed of information processing, or AD CSF biomarkers. Similarly, there was no difference regarding specific clinical symptoms: fluctuations, psychotic phenomena, sleep behavior disorder and Parkinsonism between DLB patients with and without CMB. AD patients with CMB had increased burden of WMH compared to those without (2.1 ± 0.86 vs. 1.4 ± 0.89; p = 0.005), according to Fazekas scale, whereas no significant difference was observed in DLB patients (1.68 ± 0.95 vs. 1.42 ± 0.91; p = 0.25). CONCLUSION: CMB were equally prevalent with similar topographic distribution in both DLB and AD patients. CMB was not associated with CSF AD biomarkers or core clinical symptoms in DLB.


Subject(s)
Alzheimer Disease , Lewy Body Disease , Amyloid beta-Peptides , Biomarkers , Cerebral Hemorrhage , Cross-Sectional Studies , Humans , Peptide Fragments , Retrospective Studies
7.
BMC Geriatr ; 21(1): 52, 2021 01 14.
Article in English | MEDLINE | ID: mdl-33446113

ABSTRACT

BACKGROUND: Stroke in the course of coronavirus disease (COVID-19) has been shown to be associated with more severe respiratory symptoms and higher mortality, but little knowledge in this regard exists on older populations. We aimed to investigate the incidence, characteristics, and prognosis of acute stroke in geriatric patients hospitalized with COVID-19. METHODS: A monocentric cross-sectional retrospective study of 265 older patients hospitalized with COVID-19 on acute geriatric wards. 11/265 presented a stroke episode during hospitalization. Mortality rates and two-group comparisons (stroke vs non-stroke patients) were calculated and significant variables added in logistic regression models to investigate stroke risk factors. RESULTS: Combined ischemic and hemorrhagic stroke incidence was 4.15%. 72.7% of events occurred during acute care. Strokes presented with altered state of consciousness and/or delirium in 81.8%, followed by a focal neurological deficit in 45.5%. Ischemic stroke was more frequently unilateral (88.8%) and localized in the middle cerebral artery territory (55.5%). Smoking and a history of previous stroke increased by more than seven (OR 7.44; 95% CI 1.75-31.64; p = 0.007) and five times (OR 5.19; 95% CI 1.50-17.92; p = 0.009), respectively, the risk of stroke. Each additional point in body mass index (BMI) reduced the risk of stroke by 14% (OR 0.86; 95% CI 0.74-0.98; p = 0.03). In-hospital mortality (32.1% vs. 27.3%; p > 0.999) and institutionalization at discharge (36.4% vs. 21.1%; p = 0.258) were similar between patients with and without stroke. CONCLUSION: Incident stroke complicating COVID-19 in old patients was associated with active smoking, previous history of stroke, and low BMI. Acute stroke did not influence early mortality or institutionalization rate at discharge.


Subject(s)
COVID-19 , Coronavirus , Stroke , Aged , Cross-Sectional Studies , Humans , Incidence , Retrospective Studies , Risk Factors , SARS-CoV-2 , Stroke/diagnosis , Stroke/epidemiology
8.
Clin Oral Investig ; 25(3): 875-882, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32651644

ABSTRACT

OBJECTIVES: The study aimed to compare the acetaminophen administration efficacy or its combination with codeine for pain control in acute apical abscesses cases. MATERIALS AND METHODS: Thirty-nine patients who sought emergency treatment in the Faculty of Dentistry of the Federal University of Rio Grande do Sul were included, all of them with acute apical abscess diagnosis. These patients were divided into two groups: acetaminophen group-prescription of acetaminophen (1000 mg) and acetaminophen-codeine group-prescription of acetaminophen (1000 mg) + codeine (30 mg), both with oral intake every 6 h for 3 days. The pain scores were recorded by the patients on their own at 6, 12, 24, 48, and 72 h after finishing clinical assistance, by filling a pain evolution journal, containing a visual analogue scale (VAS). Student t test was conducted to investigate different mean ages between groups 1 and 2. A comparison of weight and means of initial pain scores between groups was carried out using the Mann-Whitney U test. Chi-square test was performed to compare gender, affected tooth, education, initial swelling, and frequency of adverse effect between test and control groups. Mann-Whitney U test was applied to compare groups in the same period. Friedman's test was used to compare results from the same group over time. RESULTS: Both groups showed score reduction over time (P < 0.05). Paracetamol-codeine group showed significant pain score reduction at 48 h registers when compared to baseline and at 6 h scores (P < 0.05). Further, pain scores at 72 h were significantly lower, when compared to the baseline, at 6 h, and at 12 h scores (P < 0.05). Acetaminophen group showed significant pain score reduction observed at 72 h, when compared to the baseline and at 6 h scores (P < 0.05). There were no significant differences in pain score reduction over time between groups (P > 0.05). There was no difference between the groups regarding the frequency of adverse reactions (P > 0.05). CONCLUSION: Both medications were effective for pain control in acute apical abscess cases. The findings might have inferred in pain control of acute apical abscess associated pain in patients who used an antibiotic drug. External validity of the findings for acute apical abscess cases with no need for an antibiotic prescription is uncertain. CLINICAL RELEVANCE: This paper suggests acetaminophen 1000 mg can be used for pain control in the treatment of acute apical abscess associated with systemic manifestation.


Subject(s)
Acetaminophen , Analgesics, Non-Narcotic , Abscess , Acetaminophen/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Analgesics, Opioid/therapeutic use , Codeine/therapeutic use , Double-Blind Method , Drug Combinations , Humans , Pain , Pain, Postoperative
9.
Molecules ; 26(13)2021 Jun 25.
Article in English | MEDLINE | ID: mdl-34202190

ABSTRACT

Background: The disease caused by hepatitis C virus (HCV) is asymptomatic, silent, and progressive liver disease. In HCV-infected patients the increase in serum HA is associated with the development of hepatic fibrosis and disease progression. Methods: HCV-RNA detection was performed in all serological samples of blood donors that tested positive using HCV Ultra ELISA. Determination of hyaluronan (HA) was performed in positive HCV samples using ELISA-like fluorometric method. The HA content was compared to HCV viral load, genotype of the virus, liver fibrosis as well as ALT and GGT liver biomarkers. Results: Persistently normal ALT (<40 U/L) and GGT (<50 U/L) serum levels were detected in 75% and 69% of the HCV-Infected blood donors, respectively. Based on ROC analysis, the HA value < 34.2 ng/mL is an optimal cut-off point to exclude HCV viremia (specificity = 91%, NPV = 99%). Applying HA value ≥34.2 ng/mL significant liver fibrosis (≥F2) can be estimated in 46% of the HCV-infected blood donors. HA serum level (≥34.2 ng/mL) associated with a high ALT level (>40 U/mL) can correctly identify HCV infection and probable liver fibrosis (sensitivity = 96% and specificity = 90%) in asymptomatic blood donors. Conclusions: A high level of HA (≥34.2 ng/mL) in association with ALT (≥40 U/L) in serum can provide a good clinical opportunity to detect HCV-infected asymptomatic persons that potentially require a liver biopsy confirmation and antiviral treatment to prevent the development of advanced liver fibrosis or cirrhosis.


Subject(s)
Blood Donors , Hepacivirus/metabolism , Hepatitis C/blood , Hepatitis C/diagnosis , Hyaluronic Acid/blood , Liver Cirrhosis/blood , Liver Cirrhosis/diagnosis , Adult , Enzyme-Linked Immunosorbent Assay , Female , Genotype , Hepacivirus/genetics , Hepatitis C/genetics , Humans , Liver Cirrhosis/genetics , Male , Middle Aged
10.
Eur J Nucl Med Mol Imaging ; 47(2): 247-255, 2020 02.
Article in English | MEDLINE | ID: mdl-31792573

ABSTRACT

PURPOSE: The A/T/N model is a research framework proposed to investigate Alzheimer's disease (AD) pathological bases (i.e., amyloidosis A, neurofibrillary tangles T, and neurodegeneration N). The application of this system on clinical populations is still limited. The aim of the study is to evaluate the topography of T distribution by 18F-flortaucipir PET in relation to A and N and to describe the A/T/N status through imaging biomarkers in memory clinic patients. METHODS: Eighty-one patients with subjective and objective cognitive impairment were classified as A+/A- and N+/N- through amyloid PET and structural MRI. Tau deposition was compared across A/N subgroups at voxel level. T status was defined through a global cut point based on A/N subgroups and subjects were categorized following the A/T/N model. RESULTS: A+N+ and A+N- subgroups showed higher tau burden compared to A-N- group, with A+N- showing significant deposition limited to the medial and lateral temporal regions. Global cut point discriminated A+N+ and A+N- from A-N- subjects. On A/T/N classification, 23% of patients showed a negative biomarker profile, 58% fell within the Alzheimer's continuum, and 19% of the sample was characterized by non-AD pathologic change. CONCLUSION: Medial and lateral temporal regions represent a site of significant tau accumulation in A+ subjects and possibly a useful marker of early clinical changes. This is the first study in which the A/T/N model is applied using 18F-flortaucipir PET in a memory clinic population. The majority of patients showed a profile consistent with the Alzheimer's continuum, while a minor percentage showed a profile suggestive of possible other neurodegenerative diseases. These results support the applicability of the A/T/N model in clinical practice.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Alzheimer Disease/diagnostic imaging , Biomarkers , Cognitive Dysfunction/diagnostic imaging , Humans , Neurofibrillary Tangles , Positron-Emission Tomography
11.
Eur J Nucl Med Mol Imaging ; 47(2): 270-280, 2020 02.
Article in English | MEDLINE | ID: mdl-31388720

ABSTRACT

PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aß42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS: Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence. TRIAL REGISTRATION: EudraCT no.: 2014-005389-31.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides , Biomarkers , Cognitive Dysfunction/diagnostic imaging , Humans , Peptide Fragments , Positron-Emission Tomography , tau Proteins
12.
Rev Med Suisse ; 16(714): 2153-2155, 2020 Nov 11.
Article in French | MEDLINE | ID: mdl-33174695

ABSTRACT

The older patients have been the most affected by the SARS-CoV-2 pandemic. In addition, this infection has been responsible for high mortality rate in this population. In this article we wanted to describe the clinical findings we encountered in older people with COVID-19 and share some of the issues and challenges we faced during the COVID-19 pandemic.


Les personnes âgées ont été les plus touchées par la pandémie de SARS-CoV-2. De plus, cette infection a été responsable d'une mortalité élevée au sein de cette population. Dans cet article, nous avons souhaité décrire les particularités cliniques du Covid-19 que nous avons constatées chez les patients âgés et faire part de plusieurs enjeux et défis auxquels nous avons été confrontés au cours de la pandémie de Covid-19.


Subject(s)
Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Geriatric Assessment , Geriatrics , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Aged , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/mortality , Humans , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/mortality , SARS-CoV-2 , Switzerland/epidemiology
13.
Molecules ; 24(16)2019 Aug 17.
Article in English | MEDLINE | ID: mdl-31426507

ABSTRACT

Nowadays, pharmaceutical heparin is purified from porcine and bovine intestinal mucosa. In the past decade there has been an ongoing concern about the safety of heparin, since in 2008, adverse effects associated with the presence of an oversulfated chondroitin sulfate (OSCS) were observed in preparations of pharmaceutical porcine heparin, which led to the death of patients, causing a global public health crisis. However, it has not been clarified whether OSCS has been added to the purified heparin preparation, or whether it has already been introduced during the production of the raw heparin. Using a combination of different analytical methods, we investigate both crude and final heparin products and we are able to demonstrate that the sulfated contaminants are intentionally introduced in the initial steps of heparin preparation. Furthermore, the results show that the oversulfated compounds are not structurally homogeneous. In addition, we show that these contaminants are able to bind to cells in using well known heparin binding sites. Together, the data highlights the importance of heparin quality control even at the initial stages of its production.


Subject(s)
Anticoagulants/isolation & purification , Chondroitin Sulfates/isolation & purification , Drug Contamination , Heparin/isolation & purification , Animals , Anticoagulants/chemistry , Cattle , Chondroitin Sulfates/chemistry , Heparin/chemistry , Heparin Lyase/chemistry , Humans , Hydrolysis , Intestinal Mucosa/chemistry , Magnetic Resonance Spectroscopy , Polysaccharide-Lyases/chemistry , Quality Control , Swine
14.
Dement Geriatr Cogn Disord ; 45(5-6): 272-281, 2018.
Article in English | MEDLINE | ID: mdl-29953971

ABSTRACT

BACKGROUND: Identifying comorbidities that influence preclinical Alzheimer's disease (AD) can give some insight into the AD early stages trajectories to allow new treatment venues and to guide public health systems to prevent subsequent dementia. OBJECTIVE: To examine the association of multimorbidity with AD neuroimaging markers in cognitively normal older adults. METHODS: This study had a cross-sectional design. Data regarding 14 comorbidities were obtained for all 318 adults aged 70-85 years, recruited from the community to an ongoing prospective monocentric cohort. They underwent standardized neuropsychological and neuroimaging assessment with automated methods that measured hippocampal volumes, white matter hyperintensity volumes, fluorodeoxyglucose positron emission tomography (FDG-PET) standardized uptake values (SUV) in AD signature regions, and amyloid positron emission tomography (amyloid-PET) SUV ratios. Linear regression was used to assess the association of multimorbidity with AD neuroimaging biomarkers. RESULTS: Multimorbidity is signif icantly associated with lower hippocampal volumes (-0.03 ± 0.01; p = 0.012; R2 = 0.017) and lower FDG-PET SUV (-0.027 ± 0.009; p = 0.005; R2 = 0.022), with no association with amyloid deposition (0.001 ± 0.007; p = 0.884; R2 = 0.0001). Taken individually, obesity and excessive alcohol use are associated with lower FDG-PET values, whereas obstructive sleep apnea and mood disorders are related to lower amyloid-PET SUV ratios. CONCLUSION: Multimorbidity is associated with preclinical AD imaging markers of neurodegeneration, but not with amyloid.


Subject(s)
Alzheimer Disease , Biomarkers , Multimorbidity , Neuroimaging , Aged , Aged, 80 and over , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/physiopathology , Amyloid/metabolism , Cognition , Comorbidity , Cross-Sectional Studies , Female , Hippocampus/metabolism , Humans , Male , Positron-Emission Tomography , Prospective Studies
15.
Int Braz J Urol ; 44(6): 1139-1146, 2018.
Article in English | MEDLINE | ID: mdl-30516927

ABSTRACT

PURPOSE: The present study evaluates chondroitin sulfate (CS) and heparan sulfate (HS) in the urine and hyaluronic acid (HA) in the plasma of patients with prostate cancer before and after treatment compared to a control group. MATERIALS AND METHODS: Plasma samples were used for HA dosage and urine for quantification of CS and HS from forty-four cancer patients and fourteen controls. Clinical, laboratory and radiological information were correlated with glycosaminoglycan quantification by statistical analysis. RESULTS: Serum HA was significantly increased in cancer patients (39.68 ± 30.00 ng/ mL) compared to control group (15.04 ± 7.11 ng/mL; p=0.004) and was further increased in high-risk prostate cancer patients when compared to lower risk patients (p = 0.0214). Also, surgically treated individuals had a significant decrease in seric levels of heparan sulfate after surgical treatment, 31.05 ± 21.01 µg/mL (before surgery) and 23.14 ± 11.1 µg/mL (after surgery; p=0.029). There was no difference in the urinary CS and HS between prostate cancer patients and control group. Urinary CS in cancer patients was 27.32 ± 25.99 µg/mg creatinine while in the men unaffected by cancer it was 31.37 ± 28.37 µg/mg creatinine (p=0.4768). Urinary HS was 39.58 ± 32.81 µg/ mg creatinine and 35.29 ± 28.11 µg/mg creatinine, respectively, in cancer patients and control group (p=0.6252). CONCLUSIONS: Serum HA may be a useful biomarker for the diagnosis and prognosis of prostate cancer. However, urinary CS and HS did not altered in the present evaluation. Further studies are necessary to confirm these preliminary findings.


Subject(s)
Chondroitin Sulfates/urine , Heparitin Sulfate/urine , Hyaluronic Acid/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/urine , Aged , Biomarkers, Tumor/blood , Biomarkers, Tumor/urine , Case-Control Studies , Humans , Male , Middle Aged , Prospective Studies
16.
Public Health Nutr ; 20(16): 2847-2858, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28803598

ABSTRACT

OBJECTIVE: The present study describes the procedure and approaches needed to adapt and harmonise the GloboDiet methodology, a computer- and interview-based 24 h dietary recall, for use in two Latin American pilot countries, Brazil and Mexico. DESIGN: About seventy common and country-specific databases on foods, recipes, dietary supplements, quantification methods and coefficients were customised and translated following standardised guidelines, starting from existing Spanish and Portuguese versions. SETTING: Brazil and Mexico. SUBJECTS: Not applicable. RESULTS: New subgroups were added into the existing common food classification together with new descriptors required to better classify and describe specific Brazilian and Mexican foods. Quantification methods were critically evaluated and adapted considering types and quantities of food consumed in these two countries, using data available from previous surveys. Furthermore, the photos to be used for quantification purposes were identified for compilation in country-specific but standardised picture booklets. CONCLUSIONS: The completion of the customisation of the GloboDiet Latin America versions in these two pilot countries provides new insights into the adaptability of this dietary international tool to the Latin American context. The ultimate purpose is to enable dietary intake comparisons within and between Latin American countries, support building capacities and foster regional and international collaborations. The development of the GloboDiet methodology could represent a major benefit for Latin America in terms of standardised dietary methodologies for multiple surveillance, research and prevention purposes.


Subject(s)
Diet , Nutrition Surveys/methods , Software , Brazil , Computer Graphics , Cookbooks as Topic , Databases, Factual , Diet/adverse effects , Diet/ethnology , Food Analysis , Humans , Intersectoral Collaboration , Mexico , Nutrition Surveys/standards , Nutritive Value , Pilot Projects , Quality Control , Software Design
17.
Appetite ; 97: 120-6, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26626824

ABSTRACT

Cross-sectional and longitudinal studies present association of low dietary energy density with higher intake of vitamins, minerals and dietary fiber, lower intake of fat, and better balance of macronutrients. The objective of this study was to verify the relationship between dietary energy density and diet quality measured by an index of diet quality. This study used data from 496 adults and 445 older adults of cross-sectional population-based survey from São Paulo conducted in 2008-2009, Brazil. Dietary intake data was assessed by two 24-h dietary recalls. Dietary energy density values were calculated based on foods only method. Dietary energy density and revised Brazilian Health Eating Index and its components, were estimated by usual intake using Multiple Source Method. The relationship between dietary energy density and the total revised Brazilian Health Eating Index and its components were assessed by Gaussian family log-link model for each age group. The analyses showed an inverse association between dietary energy density and total revised Brazilian Health Eating Index in adults (T2:ß = 0.96, p < 0.001; T2:ß = 0.86, p < 0.001) and older adults (T2:ß = 0.96, p < 0.001; T2:ß = 0.90, p < 0.001), and an inverse association between dietary energy density and nine of twelve revised Brazilian Health Eating Index components in adult and/or older adults groups. Dietary energy density was associated with diet quality in Brazilian adults and older adults regardless of sex, per capita household income, body mass index, physical activity level, current smoking habits status, alcohol beverage drinking status and usual energy intake (kilocalories) from beverages.


Subject(s)
Diet , Energy Intake , Nutritive Value , Adult , Aged , Body Mass Index , Brazil , Cross-Sectional Studies , Female , Humans , Male , Mental Recall , Motor Activity , Nutrition Assessment , Socioeconomic Factors , Surveys and Questionnaires
18.
Rev Med Suisse ; 12(538): 1904-1906, 2016 Nov 09.
Article in French | MEDLINE | ID: mdl-28696594

ABSTRACT

The interaction between co-morbidities and dementia is complex. Are co-morbidities dementia or age-related ? Does one die of dementia or with dementia ? Presentation of illness is atypical in older populations but particularly so in individuals with dementia. How should one then detect and measure the co-morbidity burden, what is the best management and the most ethically correct approach to decision making ? We will discuss basic principles that can be applied to ensure optimal care of co-morbidities in people with dementia with some practical examples.


L'interaction entre les comorbidités et la démence est complexe. L'identification des comorbidités chez la personne âgée peut être difficile par une symptomatologie fruste et souvent atypique mais d'autant plus chez les patients atteints de démence. Comment devrait-on alors détecter et mesurer le fardeau d'une comorbidité ? Quelle est l'approche la plus éthiquement correcte dans le processus décisionnel ? Cet article discute des principes de base qui peuvent être appliqués pour assurer la prise en charge optimale des comorbidités chez les personnes atteintes de démence en donnant quelques exemples pratiques.


Subject(s)
Comorbidity , Decision Making , Dementia/therapy , Age Factors , Aged , Dementia/complications , Humans
19.
Eur J Immunol ; 43(9): 2373-85, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23716075

ABSTRACT

Mycobacterium avium has been reported to signal through both Toll-like receptor (TLR2) and TLR9. To investigate the role of TLR6 in innate immune responses to M. avium, TLR6, MyD88, TLR2, and TLR2/6 KO mice were infected with this pathogen. Bacterial burdens were higher in the lungs and livers of infected TLR6, TLR2, TLR2/6, and MyD88 KO mice compared with those in C57BL/6 mice, which indicates that TLR6 is required for the efficient control of M. avium infection. However, TLR6 KO spleen cells presented with normal M. avium induced IFN-γ responses as measured by ELISA and flow cytometry. In contrast, the production of IFN-γ in lung tissue was diminished in all studied KO mice. Furthermore, only MyD88 deficiency reduced granuloma areas in mouse livers. Moreover, we determined that TLR6 plays an important role in controlling bacterial growth within macrophages and in the production of TNF-α, IL-12, and IL-6 by M. avium infected DCs. Finally, the lack of TLR6 reduced activation of MAPKs and NF-κB in DCs. In summary, TLR6 is required for full resistance to M. avium and for the activation of DCs to produce proinflammatory cytokines.


Subject(s)
Mycobacterium avium Complex/immunology , Mycobacterium avium-intracellulare Infection/immunology , Toll-Like Receptor 6/immunology , Animals , Bacterial Load/immunology , Cells, Cultured , Dendritic Cells/immunology , Dendritic Cells/metabolism , Enzyme Activation , Granuloma/immunology , Humans , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Interleukin-12/biosynthesis , Interleukin-6/biosynthesis , Liver/immunology , Lung/immunology , Macrophages/immunology , Macrophages/microbiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mitogen-Activated Protein Kinases/metabolism , Myeloid Differentiation Factor 88/deficiency , Myeloid Differentiation Factor 88/genetics , Myeloid Differentiation Factor 88/immunology , NF-kappa B/metabolism , Signal Transduction/immunology , Spleen/immunology , Toll-Like Receptor 2/deficiency , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/immunology , Toll-Like Receptor 6/deficiency , Toll-Like Receptor 6/genetics , Tumor Necrosis Factor-alpha/biosynthesis
20.
J Am Med Dir Assoc ; 25(8): 105047, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38825322

ABSTRACT

OBJECTIVES: This report aimed to describe mortality at 18 months in older survivors of the first wave of COVID-19. DESIGN: Observational cohort study. SETTING AND PARTICIPANTS: Patients aged ≥65 years hospitalized for COVID-19 in the acute geriatric wards of 2 centers. METHODS: Characteristics of deceased and survivors were compared by Fisher exact, Mann-Whitney U, or 2-tailed t tests. Survival rates were analysed by Cox proportional hazards regression models. RESULTS: Of a total of 323 patients admitted during the first wave, 196 survived the acute phase, with 34 patients who died in the 18 months after hospital discharge (17.3%). Higher mortality was observed in patients living in nursing homes (P = .033) and in those who were hospitalized after discharge during the follow-up period (97.1% vs 72.8%, P = .001). There was no difference in survival curves according to age, sex, presence of dyspnea, and dementia. Living in a nursing home significantly increased the mortality rates in the multivariate model adjusted for age and sex (hazard ratio 3.07, 95% CI 1.47-6.40; P = .007). CONCLUSIONS AND IMPLICATIONS: No excess mortality was observed during 18 months in older survivors of COVID-19. Living in a nursing home was associated with decreased survival rates.


Subject(s)
COVID-19 , Nursing Homes , SARS-CoV-2 , Survivors , Humans , COVID-19/mortality , Male , Female , Aged , Aged, 80 and over , Survivors/statistics & numerical data , Cohort Studies , Proportional Hazards Models
SELECTION OF CITATIONS
SEARCH DETAIL